心不全と発射部位保存の男性と比較した女性におけるサクビトリル=バルサタン効果: PARAGON- HFからの洞察
John J V McMurray1, Alice M Jackson1, Carolyn S P Lam2,3,4
1BHF Cardiovascular Research Centre, University of Glasgow, UK (J.J.V.M., A.M.J., P.S.J.).
Circulation
|November 19, 2019
まとめ
サクビトリルバルサタンは,男性とは異なり,心不全で心不全 (HFpEF) を有する女性の入院を減少させた. これは,この状態に対する治療の有効性における性別による潜在的な違いを示唆している.
科学分野:
- 心臓病科
- 臨床試験
- 薬理学について
背景:
- 発射分子が保存された心不全 (HFpEF) は承認された治療法がないため,女性を不釣り合いに影響する.
- 男性と比較して女性ではHFpEFの治療効果が著しく低下している.
研究 の 目的:
- HFpEFに関するPARAGON- HF試験における性別特有のアウトカムを分析する.
- HFpEFを持つ女性および男性におけるサクビトリルバルサタンとバルサタンの有効性と安全性を比較する.
主な方法:
- 性別に基づくPARAGON- HF試験のサブグループ分析
- 主なアウトカム:心不全の入院と心血管疾患による死亡の複合.
- 2次結果: 生命の質と腎機能を含む有効性と安全性の測定
主要な成果:
- 女性 (51. 7%) は高齢で,肥満が多く,腎機能とNT-proBNP濃度が男性より低かった.
- サクビトリル=バルサタンは,女性では原始的アウトカム (HR 0. 73) を減少させる傾向を示したが,男性ではそうではなかった (HR 1. 03),有意な相互作用があった (P=0. 017).
- 心不全の入院が減少したのが主な利点で,女性の生活の質の改善は少なかった.
結論:
- サクビトリルバルサタンは,HFpEFを持つ男性よりも,女性の心臓不全の入院を効果的に軽減する可能性があります.
- この研究は,治療効果の性別による潜在的な変化を強調しているが,決定的なメカニズム的な説明は欠けている.
さらに関連する動画
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.9K
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.9K
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
857
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
857
01:30Heart Failure V: Medical Management
184
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
184
01:22Heart Failure Drugs: Diuretics
757
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
757
01:29Heart Failure II: Pathophysiology
633
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
633
01:22Heart Failure Drugs: β-Blockers
710
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
710
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K